World leading stem cell research and innovation.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.

 

  • Our recent research has been published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance; and presented at the American Academy of Orthopedic Surgeons Annual Meeting (New Orleans, LA, 2018), Adult Stem Cells and Regenerative Medicine Conference, The New York Academy of Sciences (NY, 2019), 7th Annual German Stem Cell Network Conference (Germany, Berlin, 2019).
  •  
  • Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice.
  •  
  • Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions.
  •  
  • The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. The study is registered at the ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT03735277).
  • The

    Problem

    The

    Solution


    Stem Cell Therapy

    Stem cells are a special kind of cell that can be used to regenerate the human body without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain. BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvesting from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby).

    The

    Opportunity


    FDA endorsed Investigator-led IND (Investigational New Drug) application

    BHI Therapeutic Sciences is initiating FDA endorsed Investigator-led IND (Investigational New Drug) clinical study of an FDA-approved cell therapy (Hematopoietic Progenitor Cell (HPC), cord blood) for treatment of acute ischemic stroke in NJ. This prospective, open-label, single-center, exploratory clinical study is designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intravenous infusion and intrathecal injection, in subjects who have sustained an acute ischemic stroke. BHI Therapeutic Sciences is in the process of preparation of Investigator-led IND application to allow for initiation of a clinical study of an FDA-approved cell therapy (HPC, cord blood) for treatment of osteoarthritis. This prospective, open-label, single-center, exploratory clinical study will be designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intra-articular injection, in subjects with osteoarthritis.

    Contact BHI Therapeutic Sciences


    BHI Therapeutic Sciences is bringing the miracle of life saving stem cell treatments to the world, and you can help. Thanks to new laws that allow anyone in the general public to invest in new and emerging companies, you can invest in BHI Therapeutic Sciences. Sign up here and be among the first to know of developments with stem cell therapy and the opening of our clinic in Texas.

    [recaptcha]


    Scroll Up